octreotide acetate / Generic mfg., Novartis  >>  Phase 3
Welcome,         Profile    Billing    Logout  

38 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
octreotide acetate / Generic mfg.
CTR20221314: To compare the safety and efficacy of lutetium [177Lu] oxyoctreotide injection versus long-acting octreotide in patients with inoperable or metastatic, progressive, well-differentiated (G1 and G2), somatostatin receptor-positive gastroenteropancreatic neu

Ongoing
3
213
China
octreotide acetate solution for injection - Generic mfg.
Beijing Xiantong International Pharmaceutical Technology Co., Ltd
Unresectable or metastatic, progressive, well-differentiated (G1 and G2) and somatostatin receptor-positive adult patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
 
 
NCT00006269: Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer

Terminated
3
89
US
irinotecan hydrochloride, octreotide acetate
Novartis
Colorectal Cancer, Diarrhea
12/99
 
NCT00128232: Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients

Completed
3
100
Europe
Octreotide LAR
Novartis
Acromegaly
08/04
 
NCT00092287 / 2004-001091-40: Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome

Terminated
3
4
US
lanreotide Autogel (somatostatin analogue), Sandostatin long acting release (LAR) Depot (somatostatin analogue)
Ipsen
Malignant Carcinoid Syndrome
 
10/04
NCT00225979: Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly

Completed
3
100
Europe
Octreotide LAR, SMS995
Novartis Pharmaceuticals
Acromegaly
03/05
03/05
NCT00241020: Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma

Completed
3
270
Europe
Octreotide
Novartis Pharmaceuticals
Advanced Hepatocellular Carcinoma
10/05
10/05
NCT00002967: Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer

Completed
3
US, Canada
cyclophosphamide, doxorubicin hydrochloride, octreotide pamoate, tamoxifen citrate
NSABP Foundation Inc, National Cancer Institute (NCI)
Breast Cancer
 
03/06
NCT00075868: Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer

Completed
3
233
US
octreotide acetate, Placebo
Radiation Therapy Oncology Group, National Cancer Institute (NCI)
Anal Cancer, Colorectal Cancer, Drug/Agent Toxicity by Tissue/Organ, Radiation Enteritis
08/06
 
NCT00175305: Prader-Willi Syndrome and Appetite

Terminated
3
10
Canada
Sandostatin LAR
University of British Columbia
Hyperphagia, Prader-Willi Syndrome
 
10/07
NCT00372697 / 2005-003444-53: Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly

Completed
3
28
Europe
Octreotide acetate 30 mg suspension, Sandostatin LAR
Novartis Pharmaceuticals
Acromegaly
10/07
10/07
NCT00002864: Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer

Completed
3
667
Canada, US
octreotide acetate, tamoxifen citrate
NCIC Clinical Trials Group
Breast Cancer
12/07
04/10
NCT00444873: Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly

Completed
3
38
Europe
lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval
Ipsen
Acromegaly
01/08
01/08
NCT00616551 / 2006-005855-14: Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients

Completed
3
65
Europe, RoW
C2L-OCT-01 PR, 30 mg, Octreotide acetate prolonged release, 30 mg, Sandostatin LAR, 30 mg
Ambrilia Biopharma, Inc.
Acromegaly
02/08
02/08
NCT00171873: Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut

Completed
3
85
Europe
Octreotide LAR (Long-acting release), SMS995, Placebo
Carmen Schade-Brittinger
Neuroendocrine Tumors
06/08
12/13
2009-012376-27: EFFECTS OF LONG-ACTING SOMATOSTATIN ON DISEASE PROGRESSION IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE AND MODERATE/SEVERE RENAL INSUFFICIENCY(ALADIN II STUDY)

Terminated
3
80
Europe
Suspension for injection, SANDOSTATINA LAR
IST. DI RICERCHE FARMACOLOG. M. NEGRI
Polycystic Kidney
 
 
RADIANT-2, NCT00412061 / 2006-004507-18: Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor

Checkmark LALCA 2014
Aug 2014 - Aug 2014: LALCA 2014
Checkmark ECCO-ESMO-ESTRO 2013
Sep 2013 - Sep 2013: ECCO-ESMO-ESTRO 2013
Checkmark P3 Data: (Everolimus + octreotide)
More
Completed
3
429
US, Canada, Europe, RoW
Octreotide, Sandostatin LAR® Depot, Placebo, Everolimus, RAD001
Novartis Pharmaceuticals
Carcinoid Tumor, Malignant Carcinoid Syndrome
04/10
06/13
LARCID, NCT00582426: Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea

Completed
3
139
RoW
Octreotide Long Acting Release, Octreotide LAR, Sandostatin LAR, Standard Treatment
Novartis Pharmaceuticals
Chemotherapy-induced Diarrhea
09/10
09/10
NCT00765323 / 2008-003327-23: Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly

Terminated
3
169
US, Europe, RoW
Octreotide Implant, somatostatin analogue, Sandostatin LAR Depot
Endo Pharmaceuticals
Acromegaly
02/11
06/11
ALADIN, NCT00309283 / 2005-005552-41: Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study

Completed
3
78
Europe
Long-acting somatostatin, Saline solution
Mario Negri Institute for Pharmacological Research
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
01/12
01/12
NCT00690430 / 2007-000739-25: Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease

Completed
3
186
US, Canada, Europe, RoW
Pasireotide, SOM230, Octreotide, Sadostatin LAR
Novartis Pharmaceuticals
Symptomatic Refractory Resistant Carcinoid Disease
04/12
04/12
PAOLA, NCT01137682 / 2009-016722-13: Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly

Completed
3
198
US, Canada, Europe, RoW
Pasireotide, SOM230, octreotide LAR 30mg, lanreotide ATG 120mg
Novartis Pharmaceuticals
Acromegaly
01/13
02/17
SWOG-S0518, NCT00569127: Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Active, not recruiting
3
427
US
Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, CT-P16, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Laboratory Biomarker Analysis, Octreotide Acetate, D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hyroxymethyl)propyl]-L-cysteinamide, Cyclic (2->7)-disulfide, Acetate (Salt), Longastatin, Longastatina, Samilstin, Sandostatin, Sandostatin LAR, Sandostatin Lar Depot, Sandostatina, Sandostatine, SMS 201-995, SMS 201-995 AC, Recombinant Interferon Alfa-2b, Alfatronol, Glucoferon, Heberon Alfa, IFN alpha-2B, Interferon alfa 2b, Interferon Alfa-2B, Interferon Alpha-2b, Intron A, Sch 30500, Urifron, Viraferon
National Cancer Institute (NCI)
Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1, Neuroendocrine Neoplasm, Neuroendocrine Tumor, Neuroendocrine Tumor G2
01/15
01/25
NETTER-1, NCT01578239 / 2011-005049-11: A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours

Completed
3
231
Europe, US
Octreotide LAR, SANDOSTATIN LAR, Octreotide, 177Lu-DOTA0-Tyr3-Octreotate, Lutathera
Advanced Accelerator Applications
Carcinoid Tumor of the Small Bowel, Neuroendocrine Tumour
07/15
01/21
2004-004696-11: A open-label extension study to evaluate the long-term safety and tolerability of Sandostatin LAR in the treatment of patients with moderately severe or severe non-proliferative diabetic retinopathy (NPDR) or low risk proliferative diabetic retinopathy

 
3
30
Europe
Sandostatin LAR, SMS995, SSTN LAR, SSTN LAR
Novartis Pharma Services AG, Novartis Farmacéutica, S.A., NOVARTIS FARMA
Moderately severe or severe non-proliferative diabetic retinopathy (NPDR) or low risk proliferative diabetic retinopathy
 
03/06
2014-004032-19: The effectiveness of the drug octreotide to anemia in patients with small bowel bleeding due to vascualr malformations.

Ongoing
3
62
Europe
Sandostatin LAR, RVG 18236, Sandostatin LAR 20 mg, Sandostatin LAR 20 mg
Radboud University Medical Center, Radboud University Medical Center
small bowel angiodysplasias
 
 
NCT00600886 / 2007-001972-36: Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly

Completed
3
358
US, Canada, Europe, RoW
Pasireotide, SOM230, Octreotide
Novartis Pharmaceuticals
Acromegaly
03/16
03/16
ALADIN2, NCT01377246 / 2011-000138-12: Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency

Completed
3
100
Europe
Octreotide-LAR, Saline solution.
Mario Negri Institute for Pharmacological Research
Autosomal Dominant Polycystic Kidney Disease
10/17
10/17
OCEAN, NCT02384122: Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias

Completed
3
62
Europe
Octreotide, Sandostatin LAR, RVG 18236, ATC H01CB02
Radboud University Medical Center, Jeroen Bosch Ziekenhuis, Elisabeth-TweeSteden Ziekenhuis, Catharina Ziekenhuis Eindhoven, Bernhoven Hospital, Tjongerschans hospital, Gelre Hospitals, Maasstad Hospital, Reinier de Graaf Groep, University Medical Center Groningen, Rijnstate Hospital, St. Antonius Hospital
Angiodysplasia, Vascular Malformations, Gastrointestinal Hemorrhage, Anemia
07/22
05/23
2022-000507-12: A randomized, controlled, open-label study of RYZ101 compared with standard of care therapy in subjects with inoperable, advanced, SSTR+ well-differentiated GEP-NET that has progressed following 177Lu SSA therapy Ensayo aleatorizado, controlado y abierto de RYZ101 frente al tratamiento habitual en sujetos con tumores neuroendocrinos gastroenteropancreáticos bien diferenciados SSTR+, avanzados e inoperables, que hayan progresado tras tratamiento con 177Lu SSA.

Not yet recruiting
3
288
Europe
RYZ101, Sunitinib, RYZ101, Sunitinib, L01XE04, Solution for injection, Tablet, Capsule, hard, Powder and solvent for suspension for injection, Solution for injection in pre-filled syringe, Everolimus Zentiva 5mg Tabletten, Szunitinib Mylan 12,5 mg, Sandostatin® LAR®- Monatsdepot 30 mg powder and solvent for suspension for injection, SOMATULINE AUTOGEL 120 mg solution for injection in a pre-filled syringe, Szunitinib Sandoz 12,5 mg
RayzeBio, Inc., RayzeBio, Inc.
gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) Tumores neuroendocrinos gastroenteropancreáticos, gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) Tumores neuroendocrinos gastroenteropancreáticos, Diseases [C] - Cancer [C04]
 
 
NETTER-2, NCT03972488 / 2019-001562-15: Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

Active, not recruiting
3
226
Europe, Canada, US, RoW
Lutathera, long-acting octreotide, high dose long-acting octreotide, Optional post-progression re-treatment with Lutathera, Optional post-progression cross-over to Lutathera, Optional post-progression re-treatment with Lutathera after cross-over
Advanced Accelerator Applications
Gastro-enteropancreatic Neuroendocrine Tumor
07/23
10/27
SORENTO, NCT05050942 / 2021-000849-40: A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET

Active, not recruiting
3
332
Europe, Canada, US, RoW
CAM2029, Octreotide LAR, Lanreotide ATG
Camurus AB
Gastro-enteropancreatic Neuroendocrine Tumor
12/24
12/26
NCT05459844: A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs

Recruiting
3
196
RoW
Lutetium[177Lu] Oxodotreotide Injection, 177Lu-DOTA0-Tyr3-Octreotate, Octreotide LAR, SANDOSTATIN LAR, Octreotide
Sinotau Pharmaceutical Group
Neuroendocrine Tumors
12/24
12/28
ACTION-1, NCT05477576: Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Active, not recruiting
3
288
Europe, Canada, US, RoW
RYZ101, Everolimus 10 mg, Sunitinib 37.5 MG, Octreotide LAR 60 MG Injection, Lanreotide 120Mg Sa Susp Inj Syringe
RayzeBio, Inc.
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET
07/25
07/28
NCT05884255: An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Recruiting
3
220
RoW
Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide, long-acting Octreotide.
Jiangsu HengRui Medicine Co., Ltd.
Advanced Gastroenteropancreatic Neuroendocrine Tumor
12/26
10/30
NCT00240045: The Use of Drugs to Improve Kidney Function in Patients With Liver and Kidney Dysfunction

Completed
2/3
9
Canada
Midodrine, albumin, octreotide LAR, midodrine, octreotide, albumin
University of Alberta, Novartis
Type 2 Hepatorenal Syndrome, Refractory Ascites
 
07/07
SS-HCC, NCT00495846: GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma

Completed
2/3
25
Europe
Octreotide-LAR, Lanreotide Autogel, Sandostatin-LAR, Ipstyl 120 mg, Somatuline Depot, Locoregional treatments
Federico II University, Ospedali dei Colli
Advanced Hepatocellular Carcinoma
04/08
12/08
NCT00426153: Octreotide in Severe Polycystic Liver Disease

Completed
2/3
42
US
Octreotide, Octreotide LAR® Depot, Placebo, Placebo injection
Mayo Clinic, Novartis, National Center for Research Resources (NCRR)
Polycystic Kidney, Autosomal Dominant, Polycystic Liver Disease, Hepatomegaly, Liver Diseases, Kidney, Polycystic, Abdominal Pain
10/08
10/08
NCT01744249 / 2011-001550-29: Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas

Active, not recruiting
2/3
255
Europe
Axitinib, Sandostatin LAR, Placebo
Grupo Espanol de Tumores Neuroendocrinos, Pfizer
Neuroendocrine Tumors, Advanced Cancer
08/21
10/21

Download Options